Gain Therapeutics Shares Skyrocket After Preclinical Data From Parkinson's Program

Gain Therapeutics Inc GANX has presented new preclinical data from its Parkinson's Disease (PD) program at the 2022 Synuclein Meeting. 

• The data show that the lead compound GT-02287 increases the levels and activity of the beta-glucocerebrosidase (GCase) protein, improves lysosomal health, and corrects abnormal phenotypes of PD.
• The data also showed improved neuronal network connections and neuron survival.
• Related: Gain Therapeutics Posts Encouraging Preclinical Data From Parkinson's, Alzheimer's Programs.
• The data were generated in two different in vitro models covering both WT and the two most pathogenic GBA1 mutations, L444P and N370S. 
• Price Action: GANX shares surged 43.2% at $6.00 during the market session on the last check Tuesday.